-
New Characteristics of BL/BLI Compounds Targeting Non-KPC Enterobacterales
Background The rise of carbapenem-resistant Gram-negative organisms (CRO) poses a significant public health challenge, prompting researchers to focus on developing new antimicrobial agents and enhancing infection control and antimicrobial stewardship…
-
Ivosidenib in Chinese Patients with Relapsed or Refractory IDH1-Mutated Acute Myeloid Leukemia: A Registry Study
In June 2024, Blood Science published an important study led by Dr. Jie Jin and colleagues from the The First Affiliated Hospital, Zhejiang University School of Medicine, investigating the safety, pharmacokinetics, and efficacy of ivosidenib in Chinese patients with relapsed or refractory (R/R) isocitrate dehydrogenase 1 (IDH1)-mutated acute myeloid leukemia (AML). AML, a heterogeneous and…
-
Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study
In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is…
-
Targeting HMGCS1 Restores Chemotherapy Sensitivity in Acute Myeloid Leukemia
In June 2024, Blood Science published a groundbreaking study led by Dr. Hui Zeng and colleagues from the The First Affiliated Hospital of Jinan University , focusing on the role of 3-hydroxy-3-methylglutaryl coenzyme A synthase 1 (HMGCS1) in acute myeloid leukemia (AML). AML is a severe hematological malignancy characterized by the rapid proliferation of immature…
-
Pomalidomide Enhances CAR-T Therapy Effectiveness in Hematological Malignancies: A Promising Synergy
Relapsed and refractory multiple myeloma (R/R MM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) represent some of the most formidable challenges in hematology. These conditions often carry a bleak prognosis due to their resistance to conventional therapies and the complex nature of extramedullary disease, where cancer cells spread outside the bone marrow. Chimeric antigen receptor…
-
Interview with Dr. Swaminathan P iyer at the EHA 2024: Exploring Breakthroughs in Secondary HLH Treatment with ELA26
At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100%…
-
Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study
In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is…
-
Dr. Lai Wei: Interpretation of Key Points from the 2024 Edition of the Chinese Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic
Hepatology Digest: Metabolic-associated fatty liver disease (MAFLD) is one of the most prevalent liver diseases globally, posing a severe threat and burden. Can you discuss the current epidemiological status of…
Connecting Medical Expertise through Media